PL1779858T3 - Zastosowanie związków selenu, w szczególności drożdży selenowych, do zmieniania funkcji poznawczych - Google Patents
Zastosowanie związków selenu, w szczególności drożdży selenowych, do zmieniania funkcji poznawczychInfo
- Publication number
- PL1779858T3 PL1779858T3 PL06007443T PL06007443T PL1779858T3 PL 1779858 T3 PL1779858 T3 PL 1779858T3 PL 06007443 T PL06007443 T PL 06007443T PL 06007443 T PL06007443 T PL 06007443T PL 1779858 T3 PL1779858 T3 PL 1779858T3
- Authority
- PL
- Poland
- Prior art keywords
- selenium
- cognitive function
- yeasts
- present
- compounds
- Prior art date
Links
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title abstract 4
- 229910052711 selenium Inorganic materials 0.000 title abstract 4
- 239000011669 selenium Substances 0.000 title abstract 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 title 1
- 230000003920 cognitive function Effects 0.000 title 1
- 229940065287 selenium compound Drugs 0.000 title 1
- 150000003343 selenium compounds Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 abstract 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960002718 selenomethionine Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72701805P | 2005-10-14 | 2005-10-14 | |
| US72692205P | 2005-10-14 | 2005-10-14 | |
| US72695105P | 2005-10-14 | 2005-10-14 | |
| US72701505P | 2005-10-14 | 2005-10-14 | |
| EP06007443A EP1779858B1 (en) | 2005-10-14 | 2005-11-07 | Use of selenium compounds, especially selenium yeasts for altering cognitive function |
| EP05024235A EP1774972B1 (en) | 2005-10-14 | 2005-11-07 | Use of selenium yeasts in the treatment of Alzheimers disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1779858T3 true PL1779858T3 (pl) | 2013-06-28 |
Family
ID=35734026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05024235T PL1774972T3 (pl) | 2005-10-14 | 2005-11-07 | Zastosowanie drożdży selenowych do leczenia choroby Alzheimera |
| PL06007443T PL1779858T3 (pl) | 2005-10-14 | 2005-11-07 | Zastosowanie związków selenu, w szczególności drożdży selenowych, do zmieniania funkcji poznawczych |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05024235T PL1774972T3 (pl) | 2005-10-14 | 2005-11-07 | Zastosowanie drożdży selenowych do leczenia choroby Alzheimera |
Country Status (14)
| Country | Link |
|---|---|
| EP (5) | EP2087895A1 (pl) |
| JP (1) | JP4753683B2 (pl) |
| CN (2) | CN102764279B (pl) |
| AT (1) | ATE547107T1 (pl) |
| AU (1) | AU2005227420B2 (pl) |
| CY (1) | CY1112790T1 (pl) |
| DK (2) | DK1779858T3 (pl) |
| ES (2) | ES2382334T3 (pl) |
| HR (1) | HRP20120337T1 (pl) |
| PL (2) | PL1774972T3 (pl) |
| PT (2) | PT1779858E (pl) |
| RS (2) | RS52257B (pl) |
| SI (1) | SI1774972T1 (pl) |
| TW (1) | TWI319708B (pl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2004204B1 (en) | 2006-03-29 | 2012-09-12 | Velacor Therapeutics Pty Ltd | Treatment of neurodegenerative diseases with selenate |
| CA2650309C (en) * | 2006-04-24 | 2014-08-19 | Alltech, Inc. | Selenium-containing compositions and use of the same |
| NZ576195A (en) | 2006-10-10 | 2012-04-27 | Az Univ Amsterdam | Complement inhibition for improved nerve regeneration |
| US7696251B2 (en) | 2007-02-12 | 2010-04-13 | Incorporated National University Iwate University | Method for inhibiting neuronal cell death induced by oxidative glutamate toxicity |
| WO2008119109A1 (en) * | 2007-03-29 | 2008-10-09 | Velacor Therapeutics Pty Ltd | Treatment of neurological disorders |
| US8987245B2 (en) | 2008-04-02 | 2015-03-24 | Jonathan R. Brestoff Parker | Composition and method for affecting obesity and related conditions |
| US8598150B1 (en) | 2008-04-02 | 2013-12-03 | Jonathan R. Brestoff | Composition and method for affecting obesity and related conditions |
| US9493834B2 (en) | 2009-07-29 | 2016-11-15 | Pharnext | Method for detecting a panel of biomarkers |
| DK2470213T3 (da) * | 2009-08-26 | 2014-01-20 | Milmed Ab | Sammensætning til behandling af neurodegenerative sygdomme eller lidelser, fremgangsmåde og anvendelse omfattende elektromagnetisk bestrålet gær |
| US8263752B2 (en) * | 2010-03-18 | 2012-09-11 | Alltech, Inc. | Methods for separating soluble selenoglycoproteins |
| WO2012095548A2 (es) * | 2011-01-13 | 2012-07-19 | Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) | Compuestos para el tratamiento de enfermedades neurodegenerativas |
| US9833486B2 (en) * | 2013-03-15 | 2017-12-05 | Alltech, Inc. | Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction |
| BR112016000106B1 (pt) | 2013-07-09 | 2023-11-21 | Annexon, Inc. | Anticorpos anti-c1q e usos dos mesmos, célula de hibridoma, composição farmacêutica e métodos de detecção de sinapses em uma amostra biológica referências cruzadas a pedidos relacionados |
| CN103848898B (zh) * | 2014-02-17 | 2016-01-27 | 南昌大学 | 双酚A的抗原模拟表位Ph3及其应用 |
| BR112016020233B1 (pt) * | 2014-03-14 | 2022-07-19 | Alltech Inc. | Composições de compostos seleno orgânicos e seus usos |
| WO2016073685A1 (en) | 2014-11-05 | 2016-05-12 | Annexon, Inc. | Humanized anti-complement factor c1q antibodies and uses thereof |
| CN104825498A (zh) * | 2015-03-30 | 2015-08-12 | 安徽省华信生物药业股份有限公司 | 硒酵母在阿尔茨海默病防治中的应用 |
| WO2017048252A1 (en) * | 2015-09-15 | 2017-03-23 | Alltech, Inc. | Compositions of selenoorganic compounds and methods of use thereof |
| EP3380518B1 (en) | 2015-11-24 | 2026-03-25 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| WO2017096049A1 (en) | 2015-12-03 | 2017-06-08 | The University Of North Carolina At Pembroke | Materials for cathepsin b enhancement and methods of use |
| FI3678739T3 (fi) * | 2017-09-07 | 2024-05-21 | Childrens Hospital Philadelphia | Koostumuksia ja menetelmiä periytyvän kystatiini c -amyloidiangiopatian (hccaa) ja muiden poikkeaviin amyloidikertymiin liittyvien hermostoa rappeuttavien häiriöiden hoitoon |
| CN111458517B (zh) * | 2020-03-13 | 2022-08-16 | 深圳大学 | Selenof作为阿尔茨海默病药物靶点的应用 |
| US12486322B2 (en) | 2021-12-13 | 2025-12-02 | Annexon, Inc. | Anti-complement factor C1q antibodies with single binding arms and uses thereof |
| PL440896A1 (pl) | 2022-04-11 | 2023-10-16 | Uniwersytet Gdański | Genisteina do zastosowania w zapobieganiu utraty pamięci i zdolności poznawczych ludzi zdrowych w wyniku stopniowych występujących fizjologicznie u osób zdrowych procesów starzenia się mózgu z wiekiem jako czynnik zapobiegający i zmniejszający odkładanie się szkodliwych nierozpuszczalnych agregatów i złogów białek w mózgu, zwłaszcza beta-amyloidu |
| CN115910112A (zh) * | 2022-12-06 | 2023-04-04 | 重庆大学 | 一种帕金森病受试者包络化语音样本段分级融合方法 |
| WO2025151942A1 (pt) * | 2024-01-18 | 2025-07-24 | Moro Peres Nemecio | Suplemento alimentar particularmente indicado para prevenção do declínio cognitivo, cápsula compreendendo o dito suplemento e uso do mesmo |
| CN118308420B (zh) * | 2024-04-19 | 2025-06-03 | 东北农业大学 | 一种大豆基因Glyma.18G041900的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT397200B (de) * | 1988-06-03 | 1994-02-25 | Birkmayer Joerg Ddr | Verwendung von selenmethionin zur herstellung eines arzneimittels |
| GB9001121D0 (en) * | 1990-01-18 | 1990-03-21 | Efamol Holdings | Efa compositions and therapy |
| US5221545A (en) | 1992-03-09 | 1993-06-22 | Abbott Laboratories | Method of providing selenium in a nutritional product |
| DE4413839C1 (de) * | 1994-04-21 | 1995-10-19 | Fritz Koch Pharma Gmbh Dr Med | Kombinationspräparat |
| JPH09323939A (ja) * | 1996-06-03 | 1997-12-16 | R T Ee Assoc Kk | 抗痴呆剤 |
| NZ334124A (en) * | 1996-08-13 | 2000-10-27 | P | Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease |
| US6197295B1 (en) | 1996-09-25 | 2001-03-06 | Viva America Marketing Corporation | Dietary supplementation with, and methods for administration of yeast-derived selenium product |
| CA2290381A1 (en) * | 1997-05-21 | 1998-11-26 | Sloan-Kettering Institute For Cancer Research | Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| JPH11199599A (ja) * | 1997-12-09 | 1999-07-27 | Adriel Dell Calpio Carlos | 補体活性阻害性ペプチドおよび抗補体剤 |
| FR2774596B1 (fr) * | 1998-02-11 | 2000-03-17 | Rhone Poulenc Rorer Sa | Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer |
| WO2000012102A1 (en) * | 1998-08-31 | 2000-03-09 | Proteotech, Inc. | Blended compositions for treatment of alzheimer's disease and other amyloidoses |
| ATE362486T1 (de) * | 1999-04-06 | 2007-06-15 | Univ California | Menschliche, für neurogenin 3 kodierende nukleotidsequenzen |
| CA2325041A1 (en) * | 2000-11-17 | 2002-05-17 | Eddie Lo | Ultra-vit. plus |
| DE10158180A1 (de) * | 2001-11-28 | 2003-09-11 | Biovision Ag | Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung |
| US7033831B2 (en) * | 2001-12-07 | 2006-04-25 | Geron Corporation | Islet cells from human embryonic stem cells |
| GB0202900D0 (en) * | 2002-02-07 | 2002-03-27 | Laxdale Ltd | Novel formulations of drugs |
| DK174835B1 (da) * | 2002-03-15 | 2003-12-15 | Pharma Nord Aps | Selengærprodukt, fremgangsmåde til fremstilling af et selengærprodukt samt anvendelse af produktet til fremstilling af en fødevare, et kosttilskud, eller et lægemiddel |
| CN1403017A (zh) * | 2002-10-24 | 2003-03-19 | 田轩 | 富硒魔芋绿茶保健食品 |
| US6911550B2 (en) | 2003-02-21 | 2005-06-28 | Zinpro Corporation | Derivatives of seleno-amino acids with improved bioavailability and method for their preparation |
| CN1440665A (zh) * | 2003-04-01 | 2003-09-10 | 宁夏长宁实业（集团）有限公司乳业分公司 | 富含硒及超氧化物歧化酶乳制品及其生产方法 |
| JP2004344079A (ja) * | 2003-05-23 | 2004-12-09 | Sceti Co Ltd | チャーガを含有する健康補助食品 |
| EP1651195A4 (en) * | 2003-07-11 | 2007-10-03 | Myriad Genetics Inc | PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE |
| US20050069594A1 (en) | 2003-08-11 | 2005-03-31 | Jan Lubinski | Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer |
| UY28650A1 (es) * | 2003-12-05 | 2005-02-28 | Forest Laboratories | Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta |
| CN1569123A (zh) * | 2004-04-30 | 2005-01-26 | 成进学 | 用蛇、蜂、宏、微量元素强化中药方剂的内服功能性药剂及其生产工艺 |
-
2005
- 2005-10-28 CN CN201210286669.2A patent/CN102764279B/zh not_active Expired - Lifetime
- 2005-10-28 JP JP2005315498A patent/JP4753683B2/ja not_active Expired - Lifetime
- 2005-10-28 TW TW094138021A patent/TWI319708B/zh not_active IP Right Cessation
- 2005-10-28 AU AU2005227420A patent/AU2005227420B2/en not_active Expired
- 2005-10-28 CN CN2005101217948A patent/CN101073584B/zh not_active Expired - Lifetime
- 2005-11-07 EP EP09005967A patent/EP2087895A1/en not_active Withdrawn
- 2005-11-07 EP EP06007441A patent/EP1779856A1/en not_active Withdrawn
- 2005-11-07 EP EP06007443A patent/EP1779858B1/en not_active Expired - Lifetime
- 2005-11-07 PL PL05024235T patent/PL1774972T3/pl unknown
- 2005-11-07 EP EP06007442A patent/EP1779857A1/en not_active Withdrawn
- 2005-11-07 PT PT60074432T patent/PT1779858E/pt unknown
- 2005-11-07 RS RS20120216A patent/RS52257B/sr unknown
- 2005-11-07 SI SI200531521T patent/SI1774972T1/sl unknown
- 2005-11-07 RS RS20130074A patent/RS52666B/sr unknown
- 2005-11-07 EP EP05024235A patent/EP1774972B1/en not_active Expired - Lifetime
- 2005-11-07 ES ES05024235T patent/ES2382334T3/es not_active Expired - Lifetime
- 2005-11-07 AT AT05024235T patent/ATE547107T1/de active
- 2005-11-07 ES ES06007443T patent/ES2402365T3/es not_active Expired - Lifetime
- 2005-11-07 DK DK06007443.2T patent/DK1779858T3/da active
- 2005-11-07 PT PT05024235T patent/PT1774972E/pt unknown
- 2005-11-07 DK DK05024235.3T patent/DK1774972T3/da active
- 2005-11-07 PL PL06007443T patent/PL1779858T3/pl unknown
-
2012
- 2012-04-16 HR HRP20120337TT patent/HRP20120337T1/hr unknown
- 2012-05-28 CY CY20121100480T patent/CY1112790T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20120337T1 (hr) | 2012-05-31 |
| TW200714277A (en) | 2007-04-16 |
| CY1112790T1 (el) | 2016-02-10 |
| PT1774972E (pt) | 2012-05-21 |
| AU2005227420A1 (en) | 2007-05-03 |
| RS52257B (sr) | 2012-10-31 |
| EP1779858B1 (en) | 2013-01-09 |
| PT1779858E (pt) | 2013-04-08 |
| JP4753683B2 (ja) | 2011-08-24 |
| ATE547107T1 (de) | 2012-03-15 |
| CN102764279A (zh) | 2012-11-07 |
| EP1779856A1 (en) | 2007-05-02 |
| ES2402365T3 (es) | 2013-05-03 |
| ES2382334T3 (es) | 2012-06-07 |
| CN101073584A (zh) | 2007-11-21 |
| RS52666B (sr) | 2013-06-28 |
| PL1774972T3 (pl) | 2012-08-31 |
| TWI319708B (en) | 2010-01-21 |
| CN101073584B (zh) | 2012-10-10 |
| CN102764279B (zh) | 2015-04-01 |
| EP1774972B1 (en) | 2012-02-29 |
| EP1779858A1 (en) | 2007-05-02 |
| AU2005227420B2 (en) | 2013-05-09 |
| DK1774972T3 (da) | 2012-05-14 |
| JP2007106732A (ja) | 2007-04-26 |
| SI1774972T1 (sl) | 2012-06-29 |
| EP1774972A1 (en) | 2007-04-18 |
| EP2087895A1 (en) | 2009-08-12 |
| EP1779857A1 (en) | 2007-05-02 |
| DK1779858T3 (da) | 2013-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1779858T3 (pl) | Zastosowanie związków selenu, w szczególności drożdży selenowych, do zmieniania funkcji poznawczych | |
| IL198922A0 (en) | Chemical compounds and uses | |
| GEP20084520B (en) | Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases | |
| TW200618817A (en) | Diffractive colorants for cosmetics | |
| WO2006071960A3 (en) | Compositions and methods of treating cell proliferation disorders | |
| TW200509892A (en) | Novel aminobenzophenone compounds | |
| WO2006003388A8 (en) | Compositions and methods for treating inflammatory disorders | |
| IL191283A (en) | Compositions for treating eye irregularities | |
| EP1919302B8 (en) | Food comprising silicon | |
| TW200738659A (en) | Novel compounds | |
| MY149492A (en) | Immunoglobulins directed against nogo | |
| PL1937669T3 (pl) | Nowe pochodne benzopiranu jako „otwieracze" kanału potasowego | |
| WO2006102061A3 (en) | Methods of decreasing calcification | |
| MX2008001428A (es) | Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos. | |
| WO2006116221A3 (en) | Therapeutic combinations for the treatment or prevention of psychotic disorders | |
| TW200700071A (en) | Novel use | |
| TW200726763A (en) | Novel compound | |
| TW200738143A (en) | Use of arylanilides for seed treatment | |
| WO2006079068A3 (en) | Compositions and methods for studying and treating inflammatory diseases and disorders | |
| WO2005117543A3 (en) | N-sulfonylcarboximidamide apoptosis promoters | |
| DE602006006950D1 (de) | Zusammensetzungen, Verwendungen und Kit für die Behandlung von Dermatitis | |
| WO2010107791A3 (en) | Pyrazinoisoquinoline compounds | |
| GB0514811D0 (en) | Compounds | |
| WO2007056570A3 (en) | Levodopa compositions | |
| WO2007047803A3 (en) | Use of prolactin in the prophylactic treatment of cancer |